Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings (Live)

A. Proteasome inhibitors and chemotherapyB. CAR T cell and bispecific antigensC. There are currently no approved optionsD. Unsure

Congratulations. The correct answer is B. Patients treated with at least 4 prior lines of therapies may be candidates for recently approved T cell-directed CAR T and bispecific antigen therapies. Proteasome inhibitors and chemotherapy are used in early lines of treatment.

Sorry, the correct answer is B. Patients treated with at least 4 prior lines of therapies may be candidates for recently approved T cell-directed CAR T and bispecific antigen therapies. Proteasome inhibitors and chemotherapy are used in early lines of treatment.

A. No role; all aspects of care are delivered in the tertiary settingB. Maintain surveillance for disease progressionC. Oversee bridging therapy until the patient returns to the tertiary center for CAR T cell therapy.D. Unsure

Congratulations. The correct answer is C. The tertiary center can send patients back to the community oncology center to receive bridging therapy to maintain their status while waiting for CARTs to be developed.

Sorry, the correct answer is C. The tertiary center can send patients back to the community oncology center to receive bridging therapy to maintain their status while waiting for CARTs to be developed.

A. Increasing ferritin and CRPB. Increasing cytokine levelsC. Decreasing ICE scoresD. Unsure

Congratulations. The correct answer is A. CRS is a clinical diagnosis, rather than a laboratory diagnosis. Ferritin and C-reactive protein are easily measured surrogate markers for CRS. Increasing levels relative to baseline would prompt initiation of treatment for CRS. Cytokine levels do not influence grading or treatment. ICE scores are used to assess neurotoxicity, not CRS.

Sorry, the correct answer is A. CRS is a clinical diagnosis, rather than a laboratory diagnosis. Ferritin and C-reactive protein are easily measured surrogate markers for CRS. Increasing levels relative to baseline would prompt initiation of treatment for CRS. Cytokine levels do not influence grading or treatment. ICE scores are used to assess neurotoxicity, not CRS.

A. CRS with CAR-T therapyB. ICANS with bispecific therapyC. CRS with CAR-T therapy with bispecific therapyD. Unsure

Congratulations. The correct answer is C. Tocilizumab is approved for the treatment of CAR T-cell-induced severe or life-threatening CRS in patients treated with CAR-T therapies and is also recommended in Grade 2 or greater CRS. Tocilizumab is preferred for CRS management, although tocilizumab is not mentioned in teclistamab’s FDA prescribing information or REMS.

Sorry, the correct answer is C. Tocilizumab is approved for the treatment of CAR T-cell-induced severe or life-threatening CRS in patients treated with CAR-T therapies and is also recommended in Grade 2 or greater CRS. Tocilizumab is preferred for CRS management, although tocilizumab is not mentioned in teclistamab’s FDA prescribing information or REMS.

A. CAR T cell therapiesB. Bispecific and CAR T cell therapiesC. Dexamethasone is not recommended for ICANSD. Unsure

Congratulations. The correct answer is B. Dexamethasone is recommended for ICANS in patients treated with bispecific and CAR T cell therapies.

Sorry, the correct answer is B. Dexamethasone is recommended for ICANS in patients treated with bispecific and CAR T cell therapies.

A. During screening and evaluationB. During the ramp-up phaseC. During long term monitoring for adverse eventsD. Unsure

Congratulations. The correct answer is C. Monitoring for long-term adverse events including infections, delayed neurotoxicity, cytopenias, and B-cell aplasias.

Sorry, the correct answer is C. Monitoring for long-term adverse events including infections, delayed neurotoxicity, cytopenias, and B-cell aplasias.

YesNoStayed the same

	Strongly Agree (5)	Agree (4)	Neutral (3)	Disagree (2)	Strongly Disagree (1)
The content covered was useful and relevant to my current or future scope of practice.
The activity was fair, balanced, and free of bias.
The activity improved my knowledge of this clinical issue.
I am better able to: Review evolving treatment options in RRMM and clinical implications
I am better able to: Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
I am better able to: Identify the most common and the unique chronic toxicities associated with long-term treatment of multiple myeloma
I am better able to: Describe the core principles surrounding mitigating and managing chronic toxicities in patients being treated in the RRMM setting
I am better able to: Outline the expanding roles of nurses, APPs, and nurse navigators when patients are treated with newer options in the RRMM setting
I am better able to: Communicate/collaborate with other members of the care team on this issue.
The information learned during this activity will help improve my skills or judgment within the next six months.
The educational activity was well planned and presented.

Modify/change my practice or the practice of my team based on this educational activity.Work with my team to create/revise protocols, policies, and/or procedures with my care team.Share what I learned with other members of my care team.Make changes in how I communicate with/educate my patients.Seek additional information on topics discussed during the activity.On average, I utilized the patient treatment strategies described in this educational activity prior to my participation.No changes at this time but my knowledge of MM was improved.

	Excellent (5)	Good (4)	Acceptable (3)	Poor (2)	Very Poor (1)
Activity Rating

Please provide the following informaiton to receive your CME/CE Certificate.

Confirmation Emailexample@example.com

The certificate emails auto-generated by this form are blocked by comcast.net email addresses. Please use an alternate email address if possible, or contact CEServices@academycme.org after submitting your form. **

Medical OncologySurgical OncologyHematology/OncologyOther

This educational activity was certified for a maximum of 1.0 AMA PRA Category 1 Credits(TM), 1.0 ANCC Contact Hours, 1.0 AAPA Category 1 CME credits, and 1.0 ACPE Contact Hours.

Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings

Post-Assessment

Evaluation